The centerpiece of the Motley Fool’s “King Kong for Weight Loss” pitch is not a small, undiscovered company. It is Eli Lilly, the maker of retatrutide, and one of the largest pharmaceutical companies on earth. That is the first thing to understand about this promo: the “King Kong” drug is real and impressive, but the company behind it is no secret, and it is not cheap to own. Here is what the Lilly part of the pitch actually rests on.

The Drug at the Center

Eli Lilly (LLY) is the marquee name in the Fool’s weight-loss basket, and for a concrete reason: retatrutide. The pitch calls it the “King Kong” of weight-loss drugs, a once-weekly triple receptor agonist that hits GLP-1, GIP, and glucagon. Existing drugs like semaglutide and tirzepatide hit one or two of those receptors. Retatrutide hits all three, and the third receptor is what drives the theory that you do not just suppress appetite, you also burn more energy at rest.

The clinical data is genuinely striking. In the TRIUMPH-4 trial, participants on the 12 mg dose lost an average of 28.7% of body weight, roughly 71.2 pounds, over 68 weeks, and close to 59% achieved at least 25% weight loss. Those are numbers that approach bariatric surgery territory, which no prior GLP-1 medicine has done. The enthusiasm in the ad is not manufactured. The drug is a big deal.

The “Double Ozempic” Framing

The promo leans on two claims: that retatrutide delivers “double the weight loss results” of Ozempic and that it has “triple” biological impact. The first claim is broadly defensible, with a caveat. Ozempic is the diabetes dose of semaglutide, while the obesity label is Wegovy, which produces roughly 15% weight loss. Against that baseline, 28.7% is close to double. But it is the drug’s best Phase 3 number in a specific high-BMI osteoarthritis population, not an across-the-board result.

The second claim, “triple biological impact,” is marketing shorthand for “hits three receptors.” That third receptor also drives the side-effect profile. In the trial, vomiting occurred in about 21% of patients on retatrutide versus none on placebo, and discontinuation rates rose with dose. A drug this powerful has tolerability tradeoffs that the “King Kong” framing skips over.

The Company Behind the Drug

Lilly is already priced like the winner the promo wants you to believe you are discovering early. The stock trades around $1,281 and carries a market cap of roughly $1.14 trillion. The Fool’s own AI Health Portfolio already recommended Lilly, which means the marquee tease is partly a re-pitch of a stock its subscribers already hold. The new idea, if there is one, lives in the five smaller names bundled around it.

None of that makes Lilly a bad company. It makes it a fully discovered one. Retatrutide’s readouts are public, the analyst community covers the drug closely, and the market has already paid up for the obesity franchise plus Lilly’s broader diabetes and pipeline business. We covered the company in more detail in our Eli Lilly stock explainer.

What Actually Moves the Stock

For Lilly, the weight-loss angle is only part of the story. The company is diversified across diabetes, oncology, immunology, and neuroscience, which means retatrutide is one important program inside a very large machine. That diversification is a strength for long-term holders, but it also means the “King Kong” drug will not single-handedly move a $1.14 trillion company the way it would move a small biotech.

The oral side of the GLP-1 race is the other moving piece. Lilly’s own orforglipron is an oral candidate, which means the company is hedged on both the injectable and the pill paths. That is a sensible position, but it is also a reminder that the “pill revolution” the promo hypes is a crowded race, not a single-winner event.

The Bottom Line

Eli Lilly is the most defensible name in the basket, and retatrutide is a genuinely important drug. The problem for a new buyer is not quality, it is price and information. At over a trillion dollars in market cap, there is no “get in before the crowd” gap here. The crowd has been in for a long time. For the full teardown of how the promo frames the deadline and the six picks, see our King Kong weight loss teardown, and for the AI side of the healthcare trade, our AI healthcare stocks piece.

The Manufacturing Moonshot

One underappreciated part of the Lilly story is the sheer scale of its manufacturing buildout. A drug like retatrutide, or even the current tirzepatide franchise, only becomes a blockbuster if the company can physically make enough of it, and Lilly has been pouring billions into new plants to ease the shortages that have plagued the category. That capacity is a moat in its own right: it takes years to build and qualify a biologics facility, so the companies that got there first hold a head start that a clever molecule alone cannot close. It also means the real constraint on Lilly’s growth is not demand, which is effectively insatiable right now, but supply. For a company already worth over a trillion dollars, the next leg of the story is as much about factories as it is about the next trial readout.

Ready to see the research? Click here to access The Motley Fool’s report.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.